In re Reglan Litigation: No Federal Preemption of State Law Claim That Generic Drug Carried Inadequate Warning

In re Reglan Litigation, ___ N.J. ___ (2016).  Plaintiffs in this mass tort matter claimed that defendants, who are generic manufacturers of metoclopramide, the generic version of the drug Reglan, were liable under New Jersey’s Product Liability Act, N.J.S.A. 2A:58C-1 to -11 (“PLA”), for failure to warn about the health effects of taking metoclopramide for […]

from Appellate Law NJ Blog http://ift.tt/2bcpR1c
via IFTTT